États-Unis · Plateformes & données · Finviz

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Publié par Finviz · États-Unis il y a 3 j

PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE)-- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing…

Lire l'article complet sur Finviz Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finviz.com)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

À lire aussi

Franco-Nevada Co. (FNV.TO) - What Are Researchers Thinking About This Stock?

RLI Non-GAAP EPS of $0.86 beats by $0.33, revenue of $476.9M beats by $9.8M

SpaceX Wants a 32-Mile Pipeline Tied Into Energy Transfer's and Kinder Morgan's Florida System. Does It Matter for Either Pipeline Stock?

Colleges raced to build massive computer-science departments. Now the boom is turning to bust.

First Solar leads green energy stocks on value and free cash flow

Anthropic is AI trade's last big hope for a major IPO this year

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Partager

À lire aussi

Franco-Nevada Co. (FNV.TO) - What Are Researchers Thinking About This Stock?

RLI Non-GAAP EPS of $0.86 beats by $0.33, revenue of $476.9M beats by $9.8M

SpaceX Wants a 32-Mile Pipeline Tied Into Energy Transfer's and Kinder Morgan's Florida System. Does It Matter for Either Pipeline Stock?

Colleges raced to build massive computer-science departments. Now the boom is turning to bust.

First Solar leads green energy stocks on value and free cash flow

Anthropic is AI trade's last big hope for a major IPO this year